Stablecoin Development Corp 10-Q

ITEM 5. OTHER INFORMATION   None.   -48- Table of Contents   ITEM 6. EXHIBITS   The following exhibits are filed with or incorporated by reference into this report.   EXHIBIT INDEX     Incorporation by Reference Filed Herewith Exhibit Number Exhibit Description Form File Number Exhibit/ Form 8-K Item Reference Filing Date   2.1 Membership Unit Purchase Agreement dated September 27, 2021, by and among the Company, DERMAdoctor, the Founders and the Sellers (as defined therein) 8-K 001-3678 2.1 9/28/2021   3.1 Amended and Restated Certificate of Incorporation of NovaBay Pharmaceuticals, Inc. 10-K 001-33678 3.1 3/21/2018   3.2 Amendment to the Amended and Restated Certificate of Incorporation 8-K 001-33678 3.1 6/04/2018   3.3 Amendment to the Amended and Restated Certificate of Incorporation, as amended 8-K 001-33678 3.1 5/28/2020   3.4 Amendment to the Amended and Restated Certificate of Incorporation, as amended, dated May 24, 2021 8-K 001-33678 3.1 5/24/2021   3.5 Amendment to the Amended and Restated Certificate of Incorporation, as amended, dated January 31, 2022 8-K 001-33678 3.1 2/1/2022   3.6 Certificate of Designation for the Series B Preferred Stock 8-K 001-33678 3.1 11/1/2021   3.7 Amended and Restated Bylaws 10-K  001-33678  3.7  3/29/2022   4.1 Description of Securities 10-K 001-33678 4.1 3/29/2022   4.2 Form of Warrant pursuant to the Services Agreement with TLF Bio Innovation Lab, LLC, dated May 13, 2020 8-K 001-33678 4.1 5/18/2020   4.3 Form of July 2020 Warrant 8-K 001-33678 4.1 7/21/2020   4.4 Form of November 2021 Warrant 8-K 001-33678 4.1 11/01/2021   10.1 Office Lease by and between the Company and KBSIII Towers at Emeryville, LLC, dated August 24, 2016 (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 26, 2016) 8-K 001-33678 10.1 8/26/2016    10.2 First Amendment to Office Lease by and between the Company and KBSIII Towers at Emeryville, LLC, dated January 24, 2022 8-K 001-33678 10.2 1/28/2022   10.3+ Executive Employment Agreement with Justin M. Hall, dated January 31, 2020 (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 6, 2020) 8-K 001-33678 10.1 2/6/2020   10.4+ First Amendment to Executive Employment Agreement with Justin M. Hall, dated January 26, 2022 8-K 001-33678 10.6 1/28/2022     -49- Table of Contents   31.1 Certification of the Principal Executive Officer of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(a) or Rule 15d-14(a)         X 31.2 Certification of the Principal Financial Officer of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(a) or Rule 15d-14(a)         X 32.1 Certification by the Chief Executive Officer   of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(b) or 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18   U.S.C. 1350)         X 32.2 Certification by the Chief Financial Officer of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(b) or 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18   U.S.C. 1350)         X 101.INS Inline XBRL Instance Document         X 101.SCH Inline XBRL Taxonomy Extension Schema Document          X 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document         X 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase         X 101.LAB Inline XBRL Taxonomy Extension Labels Linkbase Document         X 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document         X 104 The Cover Page Interactive Data File, formatted in Inline XBRL (included within the Exhibit 101 attachments)         X   + Indicates a management contract or compensatory plan or arrangement   -50- Table of Contents   SIGNATURES   Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized.   Date: May 12, 2022     By: /s/   Justin Hall      Justin Hall  Chief Executive Officer, General Counsel and Director (principal executive officer)   Date: May 12, 2022     By: /s/   Andrew Jones      Andrew Jones Chief Financial Officer (principal financial officer)   -51-